Maze Therapeutics (MAZE) said late Thursday it priced its upsized initial public offering of about 8.8 million shares at $16 per share for gross proceeds of $140 million.
In addition, Maze Therapeutics said it has granted the underwriters a 30-day option to purchase up to an additional 1.3 million shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq on Friday under the symbol 'MAZE.'
The offering is expected to close on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。